| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
7,683 |
6,392 |
$592K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
9,923 |
8,211 |
$497K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
2,886 |
2,163 |
$220K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
1,545 |
1,302 |
$220K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
2,344 |
1,987 |
$177K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
1,969 |
1,660 |
$163K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
2,151 |
1,621 |
$148K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
2,113 |
1,931 |
$49K |
| D1206 |
Topical application of fluoride varnish |
1,804 |
1,482 |
$47K |
| 96127 |
|
2,593 |
2,223 |
$46K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
1,274 |
915 |
$45K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
2,326 |
1,863 |
$37K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,208 |
841 |
$29K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
641 |
537 |
$26K |
| 96160 |
|
1,784 |
1,286 |
$26K |
| 92551 |
|
1,661 |
1,357 |
$25K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,597 |
1,350 |
$25K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
597 |
561 |
$25K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
57 |
57 |
$20K |
| 90651 |
|
819 |
642 |
$18K |
| 90698 |
|
1,426 |
1,029 |
$18K |
| 90686 |
|
1,612 |
1,365 |
$16K |
| 90670 |
|
1,071 |
886 |
$14K |
| 83655 |
|
1,174 |
969 |
$14K |
| 90671 |
|
506 |
309 |
$10K |
| 90674 |
|
530 |
447 |
$9K |
| 99173 |
|
1,145 |
963 |
$9K |
| 90680 |
|
597 |
426 |
$8K |
| 85018 |
|
2,339 |
1,847 |
$5K |
| 99174 |
|
584 |
422 |
$4K |
| 90734 |
|
224 |
191 |
$4K |
| 90661 |
|
215 |
200 |
$4K |
| 36416 |
|
859 |
701 |
$4K |
| 90633 |
|
271 |
221 |
$3K |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
185 |
157 |
$3K |
| 90619 |
|
161 |
136 |
$3K |
| 90716 |
|
83 |
75 |
$2K |
| 90620 |
|
145 |
114 |
$2K |
| 90744 |
|
196 |
173 |
$2K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
144 |
143 |
$2K |
| 92015 |
Determination of refractive state |
103 |
88 |
$2K |
| 90707 |
|
72 |
54 |
$2K |
| 90656 |
|
78 |
72 |
$1K |
| 90700 |
|
110 |
92 |
$1K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
23 |
16 |
$1K |
| 90647 |
|
39 |
38 |
$489.84 |
| 81002 |
|
175 |
138 |
$455.00 |
| 91321 |
|
18 |
16 |
$435.23 |
| 90713 |
|
33 |
30 |
$414.48 |
| 90685 |
|
40 |
34 |
$298.40 |
| 83718 |
|
26 |
25 |
$208.52 |
| 90715 |
|
12 |
12 |
$200.52 |
| 90696 |
|
18 |
12 |
$115.20 |
| 90710 |
|
18 |
12 |
$115.20 |
| 82465 |
|
26 |
25 |
$110.24 |
| G0438 |
Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit |
55 |
44 |
$0.00 |